MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.880
-0.040
-2.08%
After Hours: 1.920 +0.04 +2.13% 19:53 05/22 EDT
OPEN
1.854
PREV CLOSE
1.920
HIGH
1.930
LOW
1.820
VOLUME
590.33K
TURNOVER
--
52 WEEK HIGH
2.055
52 WEEK LOW
0.6103
MARKET CAP
47.77M
P/E (TTM)
-1.8595
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PULM stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.

EPS

PULM News

More
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.)
Benzinga · 4d ago
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning session, 85 stocks hit new 52-week highs.
Benzinga · 5d ago
Pulmatrix Reports Q1 2020 Results
PR Newswire · 05/14 14:00
Pulmatrix Q1 EPS $(0.230) Up From $(0.660) YoY, Sales $2.762M
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.230) per share. This is a 65.15 percent increase over losses of $(0.660) per share from the same period last year. The company reported $2.762 million in sales
Benzinga · 05/14 13:01
Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks
TipRanks · 04/29 15:02
CNXM, ERJ among premarket losers
Seeking Alpha - Article · 04/27 13:13
Pulmatrix 8-K Shows Director Michael Higgins To Succeed Mark Iwicki As Chair
Benzinga · 04/22 17:10
Mid-Afternoon Market Update: Dow Climbs 350 Points; Tronox Holdings Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 1.5% to 23,890.31 while the NASDAQ rose 0.05% to 8,536.23. The S&P also rose, gaining 1.31% to 2,836.24.
Benzinga · 04/17 18:46

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About PULM

Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.
More

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.